Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026

Pulsenmore grows revenue but losses and financial expenses accelerate sharply.

What the company is saying

Pulsenmore frames its first-half 2026 update as a period of commercial and operational progress, highlighting a 53% year-over-year revenue increase and the sale of approximately 4,265 devices. The company emphasizes entry into the U.S. market, citing first commercial agreements, initial provider onboarding, and the launch of its e-commerce platform, though no quantitative metrics are provided for these milestones. Strategic partnerships, regulatory clearances for the ES Tera product line, and two AI grants totaling NIS 5 million (about $1.67 million) are presented as evidence of momentum and innovation. The narrative stresses scaling operations and future manufacturing expansion in Israel, with plans for automated facilities beginning in 2027. Pulsenmore also spotlights a private placement with a healthcare-focused institutional investor, raising NIS 22.5 million (about $7.5 million) in June 2026. The tone is optimistic, projecting confidence in continued growth and expanded access to remote maternal-fetal healthcare, but operational and financial risks are not directly addressed.

What the data suggests

Revenues for the six months ended June 30, 2026, reached NIS 6.1 million (about $2 million), up 53% from NIS 4 million (about $1.3 million) in the prior year period. Gross profit also rose 53% to NIS 2.2 million (about $0.7 million), but operating expenses increased by 4% to NIS 23 million (about $7.7 million). Operating loss widened slightly to NIS 20.8 million (about $7 million), while net financial expenses surged 472% to NIS 14.3 million (about $4.8 million). Total comprehensive loss increased by 51% to NIS 35 million (about $11.8 million). Cash and equivalents stood at NIS 70 million (about $23.4 million) at June 30, 2026, bolstered by a private placement that raised NIS 22.5 million (about $7.5 million) before expenses. The company sold about 4,265 devices in the first half of 2026. AI grant funding totals NIS 5 million (about $1.67 million) supporting two projects with a combined scope of NIS 9.3 million (about $3.12 million). While revenue and device sales are growing, losses and financial expenses are accelerating at a much faster rate, and the company remains far from profitability.

Analysis

The announcement adopts a positive tone, highlighting revenue growth (53% YoY) and operational milestones such as U.S. market entry, regulatory clearances, and grant awards. However, the financials reveal persistent and widening losses: operating loss increased to NIS 20.8 million and total comprehensive loss rose 51% to NIS 35 million, with net financial expenses surging 472%. While some commercial and regulatory milestones are realised, many claims (e.g., partnerships, integrations, and future manufacturing expansion) are forward-looking or lack quantitative support. The capital raise and disclosed plans for automated manufacturing signal significant future outlays, but immediate earnings impact is absent. The narrative inflates the signal by emphasizing commercial momentum and global expansion, despite the company's deteriorating financial position and the fact that most U.S. milestones are early-stage or aspirational. The data supports weak_positive due to revenue and device sales growth, but the lack of profitability and the high proportion of forward-looking claims limit the signal.

Risk flags

• ●Accelerating net financial expenses represent a significant risk, with a 472% increase year-over-year to NIS 14.3 million (about $4.8 million). This rapid rise in financial costs could further erode cash reserves and worsen overall losses if not controlled.
• ●Operating losses remain high and are increasing, reaching NIS 20.8 million (about $7 million) for the half-year. Persistent losses at this scale raise questions about the sustainability of the business model and the timeline to break-even.
• ●The company’s narrative relies heavily on forward-looking claims about U.S. expansion, partnerships, and manufacturing plans, but provides little quantitative evidence for commercial traction or partnership economics. This gap between claims and evidence increases execution risk and makes it difficult to assess the true impact of these initiatives.
• ●Capital intensity is rising, with new manufacturing operations planned for 2027 and significant grant-funded projects underway. These initiatives will require substantial ongoing investment and successful execution to deliver returns, increasing the risk of future dilution or funding shortfalls.
• ●While a healthcare-focused institutional investor participated in the June 2026 private placement, such participation does not guarantee further institutional support or future capital raises on favorable terms.

Bottom line

Pulsenmore’s first-half 2026 results show strong revenue and device sales growth, but the company’s losses and financial expenses are growing much faster than its top line. The private placement and grant funding provide a temporary cash buffer, with NIS 70 million (about $23.4 million) on hand, but the burn rate remains high and is accelerating. Most U.S. and partnership milestones are early-stage or lack quantitative detail, so the immediate financial impact is unclear. Planned automated manufacturing in Israel will require further capital and successful execution, with benefits unlikely before 2027. The most important takeaway is that while commercial progress is visible, Pulsenmore’s financial trajectory is deteriorating and the path to profitability remains uncertain. Investors should focus on evidence of margin improvement and concrete results from U.S. expansion in future updates.

Announcement summary

(NASDAQ:PLSM) Pulsenmore Ltd. reported revenues of NIS 6.1 million (approximately $2 million) for the six months ended June 30, 2026, an increase of NIS 2.1 million (approximately $0.7 million), or 53%, compared to NIS 4 million (approximately $1.3 million) for the six months ended June 30, 2025. Gross profit for the six months ended June 30, 2026, was NIS 2.2 million (approximately $0.7 million), up NIS 0.7 million (approximately $0.2 million), or 53%, from NIS 1.5 million (approximately $0.5 million) in the prior year period. Operating expenses for the six months ended June 30, 2026, were NIS 23 million (approximately $7.7 million), an increase of NIS 0.9 million (approximately $0.3 million), or 4%, compared to NIS 22.1 million (approximately $7.4 million) for the six months ended June 30, 2025. Operating loss for the six months ended June 30, 2026, was NIS 20.8 million (approximately $7 million), compared to NIS 20.6 million (approximately $6.9 million) for the six months ended June 30, 2025. Net financial expenses for the six months ended June 30, 2026, were NIS 14.3 million (approximately $4.8 million), up NIS 11.8 million (approximately $4 million), or 472%, from NIS 2.5 million (approximately $0.8 million) in the prior year period. Total comprehensive loss for the six months ended June 30, 2026, was NIS 35 million (approximately $11.8 million), compared to NIS 23.2 million (approximately $7.7 million) for the six months ended June 30, 2025. As of June 30, 2026, Pulsenmore had cash, cash equivalents, and short-term bank deposits of NIS 70 million (approximately $23.4 million). In June 2026, Pulsenmore completed a private placement with a healthcare-focused institutional investor for 1,562,500 pre-funded warrants and ordinary warrants to purchase up to 1,562,500 ordinary shares at a combined purchase price of $4.7999 per pre-funded warrant and accompanying ordinary warrant, raising gross proceeds of NIS 22.5 million (approximately $7.5 million) before expenses.

Disagree with this article?